Bod (ASX:BDA) share price soars on United States market entry

The Bod Australia Ltd (ASX: BDA) share price is soaring after the company announced its first purchased order for the United States market.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Bod Australia Ltd (ASX: BDA) share price is on the run during early morning trade. This comes after the company announced its first purchased order for the United States market. At the time of writing, the cannabis healthcare company's shares are swapping hands for 50 cents, up 5.26%.

A white cannabis leaf set against a green background with a graph going up, indicating a rising share price for ASX cannabis shares

Image source: Getty Images

What did Bod announce?

Investors are scrambling to buy Bod shares following its latest positive update in a bid to expand its revenue base.

According to this morning's release, Bod advised it has received its initial binding purchase order from Health & Happiness Group. The first of multiple orders for the CBD products are set to be launched into the United States market. This also includes three full-spectrum CBD oil extracts under its premium brand name, CBII.

The products will be available to consumers directly through ecommercial channels sometime in the current first-half of the calendar year. Consequently, Health & Happiness will commence marketing and brand campaigns to create awareness and drive sales in the United States.

The maiden order is valued at $312,000, in which Bod will received a royalty on net product sales. In addition, a cost-plus margin for the supply of the finished goods is also set to create addition revenue streams for Bod.

Delivery of the first lot of CBD products is expected to arrive in the coming months.

The addressable market for CBD consumer products in the United States is estimated to reach around US$6.9 billion by 2025. This represents four times the size that of the United Kingdom's CBD market.

Comments from the CEO

Bod CEO Jo Patterson commented:

The first US purchase order is an exciting step for Bod on two fronts, firstly as it's growing our global footprint, and secondly the US offers a significant opportunity for consumer healthcare CBD products.

Bod will continue to work with H&H to progress additional opportunities in North America. We look forward to updating shareholders on more purchase orders soon.

About the share price

Over the last 12 months, the Bod share price has accelerated to more than 100%, but is relatively flat year-to-date. The company's shares reached a 52-week high of 74 cents last December, before moving in circles.

Based on the current share price, Bod has a market capitalisation of roughly $50.2 million, with 105.8 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the week for investors this Friday.

Read more »

Woman thinking in a supermarket.
Dividend Investing

Coles stock vs Woolworths shares: Who had the better dividend this week?

Let's check the receipts on Coles and Woolies this week.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

4 ASX All Ords shares with 40% to 90% upside post-results: experts

These shares have major upside potential, according to the experts.

Read more »

Woman looking at a laptop and thinking.
Broker Notes

4 ASX shares scoring upgrades in the final week of earnings season

Brokers have increased their ratings on Sigma Healthcare, Adairs, Netwealth, and other shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Buy, hold, sell: Netwealth, Sigma Healthcare, and Wesfarmers shares

The team at Morgans has given its verdict on these shares.

Read more »

Smiling kid flexing his muscles.
Broker Notes

3 ASX 200 shares to buy post-results: broker

Morgans has reviewed these companies' FY26 reports and given them a buy rating.

Read more »

ASX board.
ASX Share Market News

Why the ASX 200 is pushing higher as rate hike fears grow

Tech stocks are leading the market rebound today.

Read more »

Small kid giving a thumbs up.
Broker Notes

9 ASX 200 shares with strengthened buy ratings this week

Brokers are positive on Paladin Energy, Coles, WiseTech, Centuria Capital, and other shares.

Read more »